2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 633

Diagnostic Delay in Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 491

Diagnostic Performance of Anti-cyclic Citrullinated Peptide (CCP) 2 and CCP3.1 Assays in Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 559

Diagnostic Utility of Individual Inflammatory Back Pain Parameters in Patients with Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 193

Diet as a Risk Factor for Rheumatoid Arthritis

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 89

Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 783

Differences in Chromatin Architecture in Treatment Naïve Pediatric Lupus Patients

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 425

Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 697

Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 726

Digital Blood Perfusion Differences Between Black Africans and Caucasians with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 659

Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 521

Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 36

Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 440

Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 502

Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naïve Patients with Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 658

Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study

SLE – Clinical Poster I: Epidemiology & Pathogenesis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].